Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan · Delayed Price · Currency is JPY 5,533.00
+27.00 (0.49%)
Aug 6, 2026, 9:53 AM JST
Kobayashi Pharmaceutical Ratios and Metrics
Market cap in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 409,309 | 403,511 | 463,131 | 503,841 | 650,295 | 704,427 | |
Market Cap Growth | 3.89% | -12.87% | -8.08% | -22.52% | -7.69% | -28.53% |
Enterprise Value | 345,017 | 346,251 | 412,429 | 409,238 | 545,580 | 602,944 |
Last Close Price | 5506.00 | 5384.23 | 6061.06 | 6493.07 | 8515.28 | 8438.17 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 133.41 | 110.37 | 46.01 | 24.77 | 32.48 | 35.73 |
Forward PE | 36.54 | 30.37 | 30.11 | 24.52 | 33.46 | 34.40 |
PS Ratio | 2.45 | 2.44 | 2.80 | 2.91 | 3.91 | 4.54 |
PB Ratio | 1.96 | 1.91 | 2.17 | 2.46 | 3.29 | 3.60 |
P/TBV Ratio | 2.13 | 2.08 | 2.40 | 2.75 | 3.52 | 3.85 |
P/FCF Ratio | 33.18 | 32.71 | - | 89.91 | 37.88 | 37.56 |
P/OCF Ratio | 15.99 | 15.77 | 41.18 | 27.44 | 20.38 | 31.42 |
PEG Ratio | 0.71 | 2.43 | 28.67 | 20.43 | 13.39 | 11.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.07 | 2.09 | 2.49 | 2.36 | 3.28 | 3.88 |
EV/EBITDA Ratio | 15.26 | 14.68 | 12.60 | 12.92 | 17.12 | 19.59 |
EV/EBIT Ratio | 25.23 | 23.32 | 16.69 | 15.97 | 20.58 | 23.23 |
EV/FCF Ratio | 27.97 | 28.07 | - | 73.03 | 31.78 | 32.15 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
Debt / FCF Ratio | - | 0.06 | - | 0.18 | 0.05 | 0.03 |
Net Debt / Equity Ratio | -0.31 | -0.33 | -0.30 | -0.38 | -0.52 | -0.55 |
Net Debt / EBITDA Ratio | -2.84 | -2.96 | -1.98 | -2.49 | -3.26 | -3.52 |
Net Debt / FCF Ratio | - | -5.67 | 4.38 | -14.07 | -6.04 | -5.78 |
Asset Turnover | 0.66 | 0.61 | 0.62 | 0.66 | 0.65 | 0.63 |
Inventory Turnover | 3.02 | 3.45 | 3.37 | 3.88 | 4.51 | 4.55 |
Quick Ratio | 2.35 | 2.04 | 2.48 | 2.37 | 2.94 | 3.24 |
Current Ratio | 3.04 | 2.48 | 3.11 | 2.82 | 3.34 | 3.59 |
Return on Equity (ROE) | 1.48% | 1.72% | 4.81% | 10.10% | 10.18% | 10.43% |
Return on Assets (ROA) | 3.37% | 3.43% | 5.80% | 6.12% | 6.52% | 6.61% |
Return on Invested Capital (ROIC) | 7.88% | 10.02% | 13.03% | 17.18% | 20.94% | 21.02% |
Return on Capital Employed (ROCE) | 6.40% | 6.90% | 11.30% | 12.10% | 13.00% | 12.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.75% | 0.91% | 2.17% | 4.04% | 3.08% | 2.80% |
FCF Yield | 3.01% | 3.06% | -3.20% | 1.11% | 2.64% | 2.66% |
Dividend Yield | 1.93% | 1.93% | 1.68% | 1.56% | 1.06% | 0.98% |
Payout Ratio | - | 209.33% | 74.55% | 35.52% | 32.51% | 31.71% |
Buyback Yield / Dilution | - | - | 1.98% | 1.67% | 1.27% | 0.05% |
Total Shareholder Return | 1.93% | 1.93% | 3.67% | 3.23% | 2.33% | 1.03% |